The inhaled monoclonal antibody IN-006 shows promise in COVID-19 treatment, with high airway antibody levels and a favorable safety profile in healthy adults.

There’s another recall to be aware of right now, and it involves nose spray. NeilMed Pharmaceuticals Inc., the manufacturer of NasoGel Spray, has issued an international recall of 89,312 of its sprays ...

The researchers have developed a targeted nasal delivery method that repurposes a drug known as WR-2721, or amifostine, traditionally administered intravenously, to address the challenges of ...

Mandatory vehicle safety inspections are no longer required for many drivers, but some local counties still require an emissions test. Emissions tests are required in major metropolitan areas ...

Doctors usually test for and diagnose autism in early childhood. However, as symptoms and severity can vary greatly, it can sometimes be difficult to diagnose. Autism is a neurological condition ...

A pimple-like bump or sore inside the nose can sometimes be due to nasal vestibulitis or nasal folliculitis. It is a bacterial infection that can develop when hair follicles become infected ...

We also measure emissions in the same stringent tests and have found a large number of cars that, although they pass official tests, emit big quantities of toxic gases such as NOx and CO. Our fuel ...

The nasal spray Spravato, which is made from the drug esketamine, had been approved in 2019 for patients who failed to respond to at least two oral antidepressants. However, it had to be used in ...

This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a standalone therapy for cases of depression that haven’t responded to other ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD ...

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Jan. 21 (UPI) --The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression. Johnson & Johnson's Spravato has been approved to treat a ...